





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61K 39/395, 31/04, 31/05, 31/06, C12N 1/21, 9/06, 11/02, C07H 21/04

WO 99/51270

(43) International Publication Date:

(11) International Publication Number:

14 October 1999 (14.10.99)

(21) International Application Number:

PCT/US99/07546

(22) International Filing Date:

6 April 1999 (06.04.99)

(30) Priority Data:

60/080,917 60/081,778 6 April 1998 (06.04.98) 14 April 1998 (14.04.98)

US US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications

Filed on

60/080,917 (CIP) 6 April 1998 (06.04.98)

TIS Filed on

60/081,778 (CIP) 14 April 1998 (14.04.98)

(71) Applicant (for all designated States except US): DALHOUSIE UNIVERSITY [CA/CA]; Arts and Administration Building, Technology Transfer Office, 6299 South Street, Halifax. Nova Scotia B3H 4H6 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GOODWIN, Avery [AG/CA]; 33 Nicole Court, Dartmouth, Nova Scotia B2Y 4P2 (CA). HOFFMAN, Paul, S. [US/CA]; .46 Klpawa Crescent, Hammonds Plains, Nova Scotia B4B 1N2 (CA).

(74) Agent: REITER, Stephen, E.; Gray Cary Ware & Freidenrich LLP, Suite 1600, 4365 Executive Drive, San Diego, CA 92121 (US).

(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,

Published

With international search report.

Before the expiration of the time limit for amending the claims_and_to be_republished in_the_event of the_receipt of amendments.

(54) Title: A NOVEL NITROREDUCTASE AND THERAPEUTIC USES THEREFOR

(57) Abstract

In accordance with the present invention, the gene responsible for metronidazole sensitivity in H. pylori has been identified. Mutational inactivation of the gene, which encodes an oxygen-insensitive NADPH nitroreductase, referred to herein as rdxA (designated HP0954 in the entire genome sequence) (Tomb et al., 1997) is the cause of naturally acquired MtzR in H. pylori. In accordance with one embodiment of the present invention, there is provided a method of employing RdxA and related compounds, optionally in conjunction with targeting compounds, to convert nitroaromatic compounds to cytotoxins for use in selectively killing or inhibiting the growth of target cell populations. In accordance with another aspect of the present invention, there is provided a method of employing RdxA and related compounds in order to convert nitroaromatic compounds to cytotoxins for use in selecting against cells expressing rdxA.